ALPN - ニバリス・セラピュ―ティクス （Alpine Immune Sciences Inc.） ニバリス・セラピュ―ティクスALPNのチャート
ALPNの企業情報
| symbol | ALPN |
|---|---|
| 会社名 | Alpine Immune Sciences Inc （ニバリス・セラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Alpine Immune Sciences Inc. formerly Nivalis Therapeutics Inc. is focused on developing a protein-based immunotherapies using Variant immunoglobulin domain (vlgD) platform technology. The vlgD platform is designed to interact with multiple targets including many present in the immune synapse. The vlgDs are developed using a process known as directed evolution. The vlgD platform exploits both known and unknown interactions at immune synapse through a process called direct evolution for patients living with cancer autominnue/inflammatory conditions and chronic infectious disease. It optimizes native immune system proteins for use as therapeutics. The Company also developed Transmembrane Immunomodulatory Protien (TIP) technology based on the vIgD platform to enhance engineered cellular therapies. TIP program is created to help companies focused on engineered cellular therapies. ニバリス・セラピュ―ティクスは、米国の臨床段階の製薬会社。嚢胞性線維症の治療薬｢N91115｣を開発している。嚢胞性線維症の中でも、｢F508del｣という嚢胞性線維症に関係した遺伝子の突然変異によって引き起こされる疾患の治療に焦点を当てる。本社はコロラド州ボルダ―。 Alpine Immune Sciences, Inc. is committed to leading a new wave of immune therapeutics. With world-class research and development capabilities, a highly productive scientific platform, and a proven management team, Alpine is seeking to create first- or best-in-class multifunctional immunotherapies via unique protein engineering technologies to improve patients' lives. Alpine has entered into strategic collaborations with leading global biopharmaceutical companies and has a diverse pipeline of clinical and preclinical candidates in development. |
| 本社所在地 | 201 Elliott Avenue West Suite 230 Seattle WA 98119 USA |
| 代表者氏名 | Mitchell H. Gold ミッチェルH.ゴールド |
| 代表者役職名 | Executive Chairman of the Board Chief Executive Officer Assistant Secretary |
| 電話番号 | +1 206-788-4545 |
| 設立年月日 | 41122 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2015年 |
| 従業員数 | 38人 |
| url | www.nivalis.com |
| nasdaq_url | https://www.nasdaq.com/symbol/alpn |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -21.83700 |
| 終値（lastsale） | 5.93 |
| 時価総額（marketcap） | 82135018.66 |
| 時価総額 | 時価総額（百万ドル） 72.71650 |
| 売上高 | 売上高（百万ドル） 0.96100 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 7.89350 |
| 当期純利益 | 当期純利益（百万ドル） -13.20900 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Alpine Immune Sciences Inc revenues decreased 52% to $705K. Net loss increased from $5.6M to $13.2M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and Development - Balancing val increase from $4.1M to $9.1M (expense) Loss on sale of intangible asset increase from $0K to $1.2M (expense). |
ALPNのテクニカル分析
ALPNのニュース
Eledon Pharmaceuticals Appoints Jan Hillson, M.D., to its Board of Directors 2021/07/02 12:00:00 Intrado Digital Media
IRVINE, Calif., July 02, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (Eledon) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis (ALS), today announced the appointment of Jan Hillson, M.D., to the companys Board of Directors. Dr. Hillson currently serves as Senior Vice President of Clinical Development at Alpine Immune Sciences, a clinical stage biopharmaceutical company dedicated to discovering and developing innovative, protein-based immunotherapies targeting the immune synapse to treat cancer and autoimmune and inflammatory diseases.
Alpine Immune Sciences Set to Join Russell 3000® Index 2021/06/08 00:00:00 BioSpace
Alpine Immune Sciences, Inc. announced Alpine is set to join the broad-market Russell 3000® Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the US market opens on June 28, 2021, according to a preliminary list of additions posted by FTSE Russell on June 4, 2021.
Oppenheimer Maintains a Buy Rating on Alpine Immune Sciences (ALPN) 2021/06/07 03:35:18 Smarter Analyst
Oppenheimer analyst Mark Breidenbach maintained a Buy rating on Alpine Immune Sciences (ALPN) yesterday and set a price target of $19.00. The post Oppenheimer Maintains a Buy Rating on Alpine Immune Sciences (ALPN) appeared first on Smarter Analyst .
Alpine Immune Sciences'' Autoimmune Disease Candidate ALPN-303 Shows Promise in Preclinical Studies 2021/06/03 12:14:52 Benzinga
Alpine Immune Sciences Inc (NASDAQ: ALPN ) has presented the preclinical data from its ALPN-303 program at the European Alliance of Associations for Rheumatology (EULAR) European Congress of Rheumatology Virtual Meeting. ALPN-303 inhibited the activity of the B cell cytokines APRIL and BAFF more potently than wild-type TACI-Fc Full story available on Benzinga.com
H.C. Wainwright Remains a Buy on Alpine Immune Sciences (ALPN) 2021/06/03 10:25:23 Smarter Analyst
In a report released today, Joseph Pantginis from H.C. The post H.C. Wainwright Remains a Buy on Alpine Immune Sciences (ALPN) appeared first on Smarter Analyst .
Eledon Pharmaceuticals Appoints Jan Hillson, M.D., to its Board of Directors 2021/07/02 12:00:00 Intrado Digital Media
IRVINE, Calif., July 02, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (Eledon) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis (ALS), today announced the appointment of Jan Hillson, M.D., to the companys Board of Directors. Dr. Hillson currently serves as Senior Vice President of Clinical Development at Alpine Immune Sciences, a clinical stage biopharmaceutical company dedicated to discovering and developing innovative, protein-based immunotherapies targeting the immune synapse to treat cancer and autoimmune and inflammatory diseases.
Alpine Immune Sciences Set to Join Russell 3000® Index 2021/06/08 00:00:00 BioSpace
Alpine Immune Sciences, Inc. announced Alpine is set to join the broad-market Russell 3000® Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the US market opens on June 28, 2021, according to a preliminary list of additions posted by FTSE Russell on June 4, 2021.
Oppenheimer Maintains a Buy Rating on Alpine Immune Sciences (ALPN) 2021/06/07 03:35:18 Smarter Analyst
Oppenheimer analyst Mark Breidenbach maintained a Buy rating on Alpine Immune Sciences (ALPN) yesterday and set a price target of $19.00. The post Oppenheimer Maintains a Buy Rating on Alpine Immune Sciences (ALPN) appeared first on Smarter Analyst .
Alpine Immune Sciences'' Autoimmune Disease Candidate ALPN-303 Shows Promise in Preclinical Studies 2021/06/03 12:14:52 Benzinga
Alpine Immune Sciences Inc (NASDAQ: ALPN ) has presented the preclinical data from its ALPN-303 program at the European Alliance of Associations for Rheumatology (EULAR) European Congress of Rheumatology Virtual Meeting. ALPN-303 inhibited the activity of the B cell cytokines APRIL and BAFF more potently than wild-type TACI-Fc Full story available on Benzinga.com
H.C. Wainwright Remains a Buy on Alpine Immune Sciences (ALPN) 2021/06/03 10:25:23 Smarter Analyst
In a report released today, Joseph Pantginis from H.C. The post H.C. Wainwright Remains a Buy on Alpine Immune Sciences (ALPN) appeared first on Smarter Analyst .
Alpine Immune Sciences Set to Join Russell 3000® Index 2021/06/08 00:00:00 BioSpace
Alpine Immune Sciences, Inc. announced Alpine is set to join the broad-market Russell 3000® Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the US market opens on June 28, 2021, according to a preliminary list of additions posted by FTSE Russell on June 4, 2021.
Oppenheimer Maintains a Buy Rating on Alpine Immune Sciences (ALPN) 2021/06/07 03:35:18 Smarter Analyst
Oppenheimer analyst Mark Breidenbach maintained a Buy rating on Alpine Immune Sciences (ALPN) yesterday and set a price target of $19.00. The post Oppenheimer Maintains a Buy Rating on Alpine Immune Sciences (ALPN) appeared first on Smarter Analyst .
Alpine Immune Sciences'' Autoimmune Disease Candidate ALPN-303 Shows Promise in Preclinical Studies 2021/06/03 12:14:52 Benzinga
Alpine Immune Sciences Inc (NASDAQ: ALPN ) has presented the preclinical data from its ALPN-303 program at the European Alliance of Associations for Rheumatology (EULAR) European Congress of Rheumatology Virtual Meeting. ALPN-303 inhibited the activity of the B cell cytokines APRIL and BAFF more potently than wild-type TACI-Fc Full story available on Benzinga.com